Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2270-2276

  Boonstra, Kirsten ^a   Van Erpecum, Karel J ^b   Van Nieuwkerk, Karin M J ^c   Drenth, Joost P H ^d   Poen, Alexander C ^e   Witteman, Ben J M ^f   Tuynman, Hans A R E ^g   Beuers, Ulrich ^a   Ponsioen, Cyriel Y ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

^f GELDERSE VALLEI HOSPITAL   (Netherlands)

^g Location Alkmaar   (Netherlands)

Author keywords

cholangitis; Crohn's disease; inflammatory bowel disease; phenotype; sclerosing; ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BACKWASH ILEITIS; BILIARY TRACT ENDOSCOPY; CHILD; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENTERITIS; FEMALE; GEOGRAPHY; GROUPS BY AGE AND SEX; HISTOPATHOLOGY; HUMAN; ILEITIS; LEFT SIDED COLITIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PANCOLITIS; PHENOTYPE; PRESCHOOL CHILD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTITIS; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLON; FEMALE; HUMANS; ILEITIS; ILEUM; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PHENOTYPE; PROCTITIS; RECTUM; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84869207527     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22938     Document Type: Article

References (34)

1. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002; 51: 562-566.
2. Boonstra K, Beuers U, Ponsioen CY,. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012 [Epub ahead of print].
3. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 91-96.
4. Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobil Pancreat Sci. 2011; 18: 154-161.
5. Metcalf J, James O,. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis. 1997; 17: 13-22.
6. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
7. Joo M, Abreu-e-Lima, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009; 33: 854-862.
8. Perdigoto R, Wiesner RH, LaRusso NF,. Inflammatory bowel disease associated with primary sclerosing cholangitis: incidence, severity and relationship to liver disease. Gastroenterology. 1991; 100: A238.
9. Jorgensen KK, Grzyb K, Lundin KE, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012; 18: 536-545.
10. Adams DH, Eksteen B,. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006; 6: 244-251.
11. Ponsioen CY, Kuiper H, Ten Kate FJ, et al. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 1999; 11: 769-774.
12. Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004; 200: 1511-1517.
13. Melton SD, Feagins LA, Saboorian MH, et al. Ileal biopsy: clinical indications, endoscopic and histopathologic findings in 10,000 patients. Dig Liver Dis. 2011; 43: 199-203.
14. Broome U, Lofberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995; 38: 1301-1305.
15. Lundqvist K, Broome U,. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997; 40: 451-456.
16. Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008; 14: 3497-3503.
17. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 22: 775-782.
18. Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut. 1998; 43: 639-644.
19. Ho GT, Seddon AJ, Therapondos G, et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol. 2005; 17: 1379-1385.
20. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 2002; 360: 1943-1944.
21. Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011; 60: 1224-1228.
22. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008; 6: 939-943.
23. Schrumpf E, Fausa O, Forre O, et al. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol. 1982; 17: 187-191.
24. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010; 138: 1102-1111.
25. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011; 43: 17-19.
26. Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011; 53: 1977-1985.
27. Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996; 110: 432-440.
28. Kornfeld D, Ekbom A, Ihre T,. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997; 41: 522-525.
29. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009; 50: 158-164.
30. Torres J, de Chambrun GP, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 34: 497-508.
31. Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2009; 15: 1331-1336.
32. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124: 889-893.
33. Wolf JM, Rybicki LA, Lashner BA,. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005; 22: 783-788.
34. Lindstrom L, Boberg KM, Wikman O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012; 35: 451-457.